source
- CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancerCG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…
- Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startupVersant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…